AU7174494A - Neuropeptide y antagonists and agonists - Google Patents

Neuropeptide y antagonists and agonists

Info

Publication number
AU7174494A
AU7174494A AU71744/94A AU7174494A AU7174494A AU 7174494 A AU7174494 A AU 7174494A AU 71744/94 A AU71744/94 A AU 71744/94A AU 7174494 A AU7174494 A AU 7174494A AU 7174494 A AU7174494 A AU 7174494A
Authority
AU
Australia
Prior art keywords
ala
arg
lys
group
homo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU71744/94A
Other languages
English (en)
Inventor
Ambikaipakan Balasubramaniam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CINCINNATI THE, University of
Original Assignee
CINCINNATI THE, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CINCINNATI THE, University of filed Critical CINCINNATI THE, University of
Publication of AU7174494A publication Critical patent/AU7174494A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU71744/94A 1993-06-18 1994-06-16 Neuropeptide y antagonists and agonists Abandoned AU7174494A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7931993A 1993-06-18 1993-06-18
US079319 1993-06-18
PCT/US1994/006837 WO1995000161A1 (fr) 1993-06-18 1994-06-16 Antagonistes et agonistes du neuropeptide y

Publications (1)

Publication Number Publication Date
AU7174494A true AU7174494A (en) 1995-01-17

Family

ID=22149788

Family Applications (1)

Application Number Title Priority Date Filing Date
AU71744/94A Abandoned AU7174494A (en) 1993-06-18 1994-06-16 Neuropeptide y antagonists and agonists

Country Status (6)

Country Link
EP (1) EP0707490A1 (fr)
JP (1) JPH11501281A (fr)
AU (1) AU7174494A (fr)
CA (1) CA2165200A1 (fr)
WO (1) WO1995000161A1 (fr)
ZA (1) ZA944338B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
EP0759441A3 (fr) * 1995-06-30 1999-06-30 Eli Lilly And Company Procédés de traitement des pathologies associées aux peptides neuropeptide Y
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
US5943242A (en) 1995-11-17 1999-08-24 Pact Gmbh Dynamically reconfigurable data processing system
FR2754709B1 (fr) * 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
WO1998027063A1 (fr) * 1996-12-16 1998-06-25 Banyu Pharmaceutical Co., Ltd. Derives d'aminopyrazole
US6542998B1 (en) 1997-02-08 2003-04-01 Pact Gmbh Method of self-synchronization of configurable elements of a programmable module
KR100891756B1 (ko) 1997-04-15 2009-04-07 씨에스아이알 식욕 억제 활성을 갖는 약학 조성물
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
GB0217015D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 4
DE602004026289D1 (de) 2003-05-05 2010-05-12 Probiodrug Ag Glutaminylcyclase-hemmer
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
AU2005210004B2 (en) 2004-02-05 2010-10-28 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2007097742A1 (fr) * 2006-02-21 2007-08-30 University Of Cincinnati Méthodes en rapport avec des récepteurs induits par des corticoïdes
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
WO2008065141A1 (fr) 2006-11-30 2008-06-05 Probiodrug Ag Nouveaux inhibiteurs de glutaminylcyclase
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
BRPI1008039A2 (pt) 2009-02-20 2016-10-04 Ipsen Pharma Sas composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
UA101435C2 (ru) * 2009-02-20 2013-03-25 Ипсен Фарма С.А.С. Аналоги нейропептида y, которые содержат по меньшей мере одну замену на синтетическую аминокислоту
US20120040886A1 (en) * 2009-02-20 2012-02-16 Zheng Xin Dong Analogues of Neuropeptide Y Having Proline Substitution At Position 34
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012123563A1 (fr) 2011-03-16 2012-09-20 Probiodrug Ag Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
WO2017034997A1 (fr) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Modulateurs phénylpipérazine proprotéine convertase subtilisine/kexine de type 9 (pcsk9) et leur utilisation
WO2017034990A1 (fr) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition et procédés d'utilisation de petites molécules de type tétrahydroisoquinoline pour se lier à pcsk9 et moduler l'activité protéique de pcsk9
EP3337497B1 (fr) 2015-08-21 2023-07-12 SRX Cardio, LLC Composition et procédés d'utilisation de nouveaux petits composés organiques de phénylalanine pour moduler directement l'activité de la protéine pcsk9
WO2017147328A1 (fr) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Composés se liant à la proprotéine convertase subtilisine/kexine de type 9 (pcsk9)
EP3461819B1 (fr) 2017-09-29 2020-05-27 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839343A (en) * 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
US5026685A (en) * 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs
ZA896376B (en) * 1988-08-26 1990-05-30 Merrell Dow Pharma Neuropeptide y agonists

Also Published As

Publication number Publication date
ZA944338B (en) 1995-02-14
EP0707490A1 (fr) 1996-04-24
JPH11501281A (ja) 1999-02-02
WO1995000161A1 (fr) 1995-01-05
CA2165200A1 (fr) 1995-01-05

Similar Documents

Publication Publication Date Title
AU7174494A (en) Neuropeptide y antagonists and agonists
US5604203A (en) Analogs of peptide YY and uses thereof
US6235718B1 (en) Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US7465710B2 (en) Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US8153599B1 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
US8729227B2 (en) Compounds for control of appetite
WO1995000542A1 (fr) Antagonistes du recepteur a la bombesine et leur utilisation
EP1015007A1 (fr) Analogues de peptide yy et leurs utilisations
US7994119B2 (en) Compounds for control of appetite
JP2002502381A (ja) 環状ｃｒｆアンタゴニストペプチド
US20070287665A1 (en) Urotensin-II agonists and antagonists
AU2002232903A1 (en) Urotensin-II agonists and antagonists
AU2005202153A1 (en) Urotensin-II agonists
EP1878743A2 (fr) Agonistes et antagonistes de l'urotensine II